title: Better off blue: BMPR-2 mutation, arteriovenous malformation, and pulmonary arterial hypertension.
authors.affiliation: 1 Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom; and.
authors.forename: Elaine
authors.initials: E
authors.lastname: Soon
authors.forename: Mark
authors.initials: M
authors.lastname: Southwood
authors.forename: Karen
authors.initials: K
authors.lastname: Sheares
authors.forename: Joanna
authors.initials: J
authors.lastname: Pepke-Zaba
authors.forename: Nicholas W
authors.initials: NW
authors.lastname: Morrell
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D001165:Arteriovenous Malformations / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D052006:Bone Morphogenetic Protein Receptors, Type II / Q000235:genetics*; D000077300:Bosentan; D018450:Disease Progression; D004359:Drug Therapy, Combination; D065627:Familial Primary Pulmonary Hypertension; D005500:Follow-Up Studies; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010375:Pedigree; D010879:Piperazines / Q000627:therapeutic use; D011651:Pulmonary Artery / Q000002:abnormalities*; D011667:Pulmonary Veins / Q000002:abnormalities*; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D010879:Piperazines; D011687:Purines; D013449:Sulfonamides; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; C498218:BMPR2 protein, human; D052006:Bone Morphogenetic Protein Receptors, Type II; D000077300:Bosentan